在GLP-1(胰高血糖素样肽-1)减肥药的竞争中诺和诺德的司美格鲁肽终于凭借心血管方面的获益扳回一局。9月1日记者从诺和

智通财经
Sep 01
在GLP-1(胰高血糖素样肽-1)减肥药的竞争中诺和诺德的司美格鲁肽终于凭借心血管方面的获益扳回一局。9月1日记者从诺和诺德中国获悉该公司在西班牙马德里举行的2025年欧洲心脏病学会(ESC)年会上公布了STEER真实世界研究的最新数据。STEER研究是一项回顾性、观察性真实世界研究评估了Wegovy(减重版司美格鲁肽2.4 mg)对比替尔泊肽在超重或肥胖且已确诊心血管疾病但无糖尿病的患者中预防主要不良心血管事件(MACE)的有效性。研究结果显示在治疗过程中用药中断不超过30天的前提下相较于替尔泊肽减重版司美格鲁肽能使超重或肥胖且伴有心血管疾病的患者心脏病发作、卒中以及心血管相关死亡或全因死亡风险降低57%。试验中减重版司美格鲁肽组记录15例(0.1%)心血管事件替尔泊肽组为39例(0.4%)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10